A landscape assessment of newborn screening in Europe
Newborn screening (NBS), or the process of identifying members of a population who may have, or may be at risk of developing, a specific disease or condition,...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Mr. Tim Wilsdon is a vice president in CRA’s Life Sciences Practice in London, England and is responsible for leading the policy sector in the global Life Sciences Practice.
He commonly talks at international conferences on issues to do with health technology assessment and pricing and reimbursement and the economics of innovation for pharmaceutical products and diagnostics. He has also acted as an expert in international arbitrations involving multinational pharmaceutical companies and was EFPIA and PhRMA’s economic expert during the DG Competition’s Sector Inquiry.
Mr. Wilsdon has completed studies for the European Commission (including DG GROW and TRADE) and the pharmaceutical industry (through EFPIA, PhRMA, and country associations such as Innovative Medicines Canada, ABPI, LIF, and IPASA) on how healthcare markets could be reformed for efficiency. He was responsible for leading an assignment for the European Commission determining whether there was a global crisis in innovation and the risks of importation. For the industry, he has undertaken assessments of health technology assessments, international reference pricing, early access agreements, managed entry agreements and many other issues.